Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Georgetown University presents new AGBL2 inhibitors

Sep. 17, 2012

FDA approves production of [11C]-choline injection for PET imaging

Sep. 14, 2012

Primary endpoint met in first stage of phase II Reolysin trial

Sep. 14, 2012

Xtandi now available in the U.S.

Sep. 14, 2012

Cancer Therapeutics CRC synthesizes novel agents for cancer

Sep. 14, 2012

Indian researchers disclose novel agents for cancer

Sep. 14, 2012

Sunesis plans to increase sample size in pivotal VALOR trial

Sep. 13, 2012

Oncolytics modifies phase III study of Reolysin

Sep. 13, 2012

e-Therapeutics begins second phase I trial of ETS-2101 in cancer

Sep. 13, 2012

Hybrigenics begins phase II trial of oral inecalcitol in CLL

Sep. 13, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
In the clinic for June 12, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Anixa, Beone, Bioinvent, Blossomhill, C4, Cellectis, Climb, Elixiron,...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...